Sign In
Buy MIRM
$91.84
-0.335 (-0.363%)
At Close: Jun 03, 2026
Mirum Pharmaceuticals, Inc. (MIRM) CEO Chris Peetz on Q3 2021 Results - Earnings Call Transcript
12:08am, Tuesday, 16'th Nov 2021
Mirum Pharmaceuticals, Inc. (MIRM) CEO Chris Peetz on Q3 2021 Results - Earnings Call Transcript
Mirum Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update
09:01pm, Monday, 15'th Nov 2021 Business Wire
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q3 Loss
06:29pm, Monday, 15'th Nov 2021
Mirum Pharmaceuticals, Inc. (MIRM) delivered earnings and revenue surprises of 4.91% and 0.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the
Mirum Pharmaceuticals: Livmarli Approval Could Spark A Bull Run For This Young Biotech
04:25am, Friday, 12'th Nov 2021
Mirum recently won approval for Livmarli in Alagille syndrome, a rare liver disorder with a market opportunity of ~$1bn. The company is heavily loss making, but has >$230m in cash which it says will b
FDA Approves First Treatment For Alagille Syndrome-Associated Cholestatic Pruritus From Mirum Pharma
04:45pm, Wednesday, 29'th Sep 2021
The FDA has approved Mirum Pharmaceuticals Inc (NASDAQ: MIRM) Livmarli (maralixibat) oral solution for cholestatic pruritus in patients with Alagille syndrome (ALGS) one year of age and older. Li
FOSTER CITY, Calif.--(BUSINESS WIRE)--FDA Approves LIVMARLI as the First and Only Approved Medication for the Treatment of Cholestatic Pruritus in Patients with ALGS
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Submits European MAA for Maralixibat in ALGS Supported by New Positive Results from Natural History Study Comparison
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05:30pm, Friday, 10'th Sep 2021
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mirum Pharmaceuticals to Participate in September Investor Conferences
05:30pm, Thursday, 02'nd Sep 2021
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Participate in September Investor Conferences
Mirum And Maralixibat In Pediatric Cholestasis: The Differentiation
03:13pm, Tuesday, 24'th Aug 2021
The expectation is that Mirum trades two-fold higher or more on regulatory approval of maralixibat for Alagille syndrome, and better than Albireo's lackluster share price performance post-regulatory s
Mirum Pharmaceuticals Appoints Biotechnology Executive William C. Fairey to its Board of Directors
05:30pm, Thursday, 19'th Aug 2021
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Appoints Biotechnology Executive William C. Fairey to its Board of Directors
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:00pm, Tuesday, 10'th Aug 2021
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mirum Pharmaceuticals, Inc. (MIRM) CEO Chris Peetz on Q2 2021 Results - Earnings Call Transcript
12:40pm, Sunday, 08'th Aug 2021
Mirum Pharmaceuticals, Inc. (MIRM) CEO Chris Peetz on Q2 2021 Results - Earnings Call Transcript
Mirum Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update
04:02pm, Thursday, 05'th Aug 2021
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update
